Cidofovir Disease Interactions
There are 3 disease interactions with cidofovir.
Cidofovir (applies to cidofovir) dehydration
Major Potential Hazard, High plausibility.
Cidofovir is associated with dose-dependent nephrotoxicity, which is minimized by adequate hydration. One liter of normal saline should be infused over 1 to 2 hours prior to each dose of cidofovir in normal adults. Therapy with cidofovir should be administered cautiously in patients who are dehydrated. These patients may be candidates for an additional liter, given over 1 to 3 hours upon the initiation or completion of cidofovir infusion.
References
- "Product Information. Vistide (cidofovir)." Gilead Sciences PROD (2001):
Cidofovir (applies to cidofovir) neutropenia
Major Potential Hazard, High plausibility.
Cidofovir may cause neutropenia (20% in clinical trials). Therapy with cidofovir should be administered cautiously in patients with preexisting neutropenia or those receiving concomitant drugs with myelosuppressive effects. With some drugs (e.g., zidovudine or AZT), a temporary interruption of therapy or a reduction in dosage may be necessary on days of cidofovir administration. Close monitoring of neutrophil count is recommended during therapy with cidofovir. Some patients may be candidates for granulocyte colony stimulating factor.
References
- "Product Information. Vistide (cidofovir)." Gilead Sciences PROD (2001):
- Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al. "(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue." J Infect Dis 171 (1995): 788-96
Cidofovir (applies to cidofovir) renal dysfunction
Major Potential Hazard, High plausibility.
The initiation of cidofovir therapy is contraindicated in patients with renal impairment defined by a serum creatinine > 1.5 mg/dL, a calculated creatinine clearance <= 55 mL/min, or a urine protein >= 100 mg/dL (i.e., 2+ proteinuria). Cidofovir is associated with dose-dependent nephrotoxicity, which may result in acute renal failure and the need for dialysis in some cases, as well as Fanconi's syndrome. Patients with normal renal function or mild dysfunction should be monitored closely for declining renal function during cidofovir therapy, and the dosing adjusted or discontinued accordingly. Renal function should be assessed within 48 hours preceding each dose.
References
- "Product Information. Vistide (cidofovir)." Gilead Sciences PROD (2001):
- Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al. "(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue." J Infect Dis 171 (1995): 788-96
- Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, et al. "Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria." Antimicrob Agents Chemother 39 (1995): 882-6
Cidofovir drug interactions
There are 127 drug interactions with cidofovir.
More about cidofovir
- cidofovir consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: purine nucleosides
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.